| Octreotide Efficacy and Safety in First-line Acromegalic Patients (NCT00171886) | Novartis Pharmaceuticals | 2002-07-01 |
| Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload (NCT00379483) | Novartis Pharmaceuticals | 2002-07-01 |
| Pediatric Epilepsy Study (NCT00050934) | Novartis Pharmaceuticals | 2002-06-01 |
| Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma (NCT00241020) | Novartis Pharmaceuticals | 2002-06-01 |
| EPO906 Therapy in Patients With Advanced Colorectal Cancer (NCT00035087) | Novartis Pharmaceuticals | 2002-05-01 |
| Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients (NCT00239902) | Novartis Pharmaceuticals | 2002-05-01 |
| Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions (NCT00171964) | Novartis Pharmaceuticals | 2002-05-01 |
| Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period (NCT00103740) | Novartis Pharmaceuticals | 2002-04-01 |
| Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment (NCT00241046) | Novartis Pharmaceuticals | 2002-04-01 |
| Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis (NCT00035997) | Novartis Pharmaceuticals | 2002-04-01 |
| EPO906 Therapy in Patients With Advanced Kidney Cancer (NCT00035243) | Novartis Pharmaceuticals | 2002-04-01 |
| EPO906 Therapy in Patients With Advanced Melanoma (NCT00035165) | Novartis Pharmaceuticals | 2002-03-01 |
| A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors (NCT00940563) | Novartis Pharmaceuticals | 2002-03-01 |
| Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture (NCT00046254) | Novartis Pharmaceuticals | 2002-02-01 |
| PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2) (NCT00045942) | Novartis Pharmaceuticals | 2002-01-30 |
| Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (NCT00097786) | Novartis Pharmaceuticals | 2002-01-01 |
| EPO906 Therapy in Patients With Advanced Breast Cancer (NCT00035126) | Novartis Pharmaceuticals | 2002-01-01 |
| HORIZON-PFT: Pivotal Fracture Trial (NCT00049829) | Novartis Pharmaceuticals | 2002-01-01 |
| A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis (NCT00036413) | Novartis Pharmaceuticals | 2002-01-01 |
| Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (NCT00172068) | Novartis Pharmaceuticals | 2002-01-01 |
| EPO906 Therapy in Patients With Prostate Cancer (NCT00035113) | Novartis Pharmaceuticals | 2002-01-01 |
| Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients (NCT00574743) | Novartis Pharmaceuticals | 2002-01-01 |
| Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma (NCT00046748) | Novartis Pharmaceuticals | 2001-12-01 |
| This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus (NCT00531063) | Novartis Pharmaceuticals | 2001-11-01 |
| This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307. (NCT00531440) | Novartis Pharmaceuticals | 2001-11-01 |
| Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant (NCT00565474) | Novartis Pharmaceuticals | 2001-09-01 |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer (NCT00035100) | Novartis Pharmaceuticals | 2001-09-01 |
| Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia (NCT00099216) | Novartis Pharmaceuticals | 2001-08-01 |
| Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer (NCT00237211) | Novartis Pharmaceuticals | 2001-06-01 |
| Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers (NCT00233337) | Novartis Pharmaceuticals | 2001-05-01 |
| Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases (NCT00154388) | Novartis Pharmaceuticals | 2001-02-01 |
| Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period (NCT00051636) | Novartis Pharmaceuticals | 2001-01-01 |
| Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I (NCT00171925) | Novartis Pharmaceuticals | 2000-08-01 |
| Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer (NCT00006370) | Novartis Pharmaceuticals | 2000-07-01 |
| A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients. (NCT00738257) | Novartis Pharmaceuticals | 2000-06-01 |
| Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients (NCT00098241) | Novartis Pharmaceuticals | 2000-06-01 |
| Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers (NCT00535418) | Novartis Pharmaceuticals | 2000-06-01 |
| A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene (NCT00237185) | Novartis Pharmaceuticals | 2000-06-01 |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (NCT00333840) | Novartis Pharmaceuticals | 2000-06-01 |
| Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107 (NCT00149916) | Novartis Pharmaceuticals | 2000-04-01 |
| A Study of Letrozole in the Treatment of Endometrial Cancer (NCT00333086) | Novartis Pharmaceuticals | 2000-01-01 |
| An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha (NCT00171223) | Novartis Pharmaceuticals | 1999-12-06 |
| Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer (NCT00247663) | Novartis Pharmaceuticals | 1999-12-01 |
| Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms (NCT00005073) | Novartis Pharmaceuticals | 1999-09-01 |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia (NCT00171249) | Novartis Pharmaceuticals | 1999-08-09 |
| An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis (NCT00171158) | Novartis Pharmaceuticals | 1999-07-26 |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer (NCT00006368) | Novartis Pharmaceuticals | 1998-01-01 |
| Canakinumab MAP in COVID-19 Pneumonia With CRS (NCT04476706) | Novartis Pharmaceuticals | |
| A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation (NCT00149981) | Novartis Pharmaceuticals | |
| Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy (NCT00655252) | Novartis Pharmaceuticals | |
| Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy (NCT00409019) | Novartis Pharmaceuticals | |
| An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) (NCT03114228) | Novartis Pharmaceuticals | |
| Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) (NCT03070691) | Novartis Pharmaceuticals | |
| Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection (NCT04544202) | Novartis Pharmaceuticals | |
| Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma (NCT04489433) | Novartis Pharmaceuticals | |
| Managed Access Programs for LEE011, Ribociclib (NCT05038631) | Novartis Pharmaceuticals | |
| MAP to Provide Access to Nilotinib, for Patients With HES (NCT04498871) | Novartis Pharmaceuticals | |
| Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness (NCT04337359) | Novartis Pharmaceuticals | |
| Managed Access Programs for INC280, Capmatinib (NCT04741789) | Novartis Pharmaceuticals | |
| Managed Access Programs for VAY736, Ianalumab (NCT07244289) | Novartis Pharmaceuticals | |
| Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer (NCT04507919) | Novartis Pharmaceuticals | |
| MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (NCT05269771) | Novartis Pharmaceuticals | |
| Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy (NCT01451450) | Novartis Pharmaceuticals | |
| Managed Access Programs for INC424, Ruxolitinib (NCT04745637) | Novartis Pharmaceuticals | |
| Managed Access Programs for EXV811, Atrasentan (NCT07319585) | Novartis Pharmaceuticals | |
| Managed Access Programs for BYL719, Alpelisib (NCT04085653) | Novartis Pharmaceuticals | |
| Managed Access Programs for LDK378, Ceritinib (NCT05100134) | Novartis Pharmaceuticals | |
| An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma (NCT02568943) | Novartis Pharmaceuticals | |
| An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (NCT01995734) | Novartis Pharmaceuticals | |
| Managed Access Programs for PKC412, Midostaurin (NCT05219266) | Novartis Pharmaceuticals | |
| Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) (NCT02389933) | Novartis Pharmaceuticals | |
| Managed Access Programs for TQJ230, Pelacarsen (NCT07000695) | Novartis Pharmaceuticals | |
| Global Managed Access Program Cohort for Ligelizumab in CSU (NCT04903613) | Novartis Pharmaceuticals | |
| Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma (NCT02204553) | Novartis Pharmaceuticals | |
| Managed Access Programs for LNP023, Iptacopan (NCT05222412) | Novartis Pharmaceuticals | |
| Managed Access Programs for CTL019, Tisagenlecleucel (NCT03601442) | Novartis Pharmaceuticals | |
| MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer (NCT05108740) | Novartis Pharmaceuticals | |
| Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease (NCT04540861) | Novartis Pharmaceuticals | |
| MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT04559555) | Novartis Pharmaceuticals | |
| Managed Access Programs for ETB115, Eltrombopag (NCT04837703) | Novartis Pharmaceuticals | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer (NCT03706573) | Novartis Pharmaceuticals | |
| Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy (NCT02624570) | Novartis Pharmaceuticals | |
| Managed Access Programs for SEG101, Crizanlizumab (NCT03720626) | Novartis Pharmaceuticals | |
| Nilotinib, for Patients With CML-CP or CML-AP (NCT04518644) | Novartis Pharmaceuticals | |
| Managed Access Programs for ABL001, Asciminib (NCT04360005) | Novartis Pharmaceuticals | |
| Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria (NCT05170724) | Novartis Pharmaceuticals | |
| Managed Access Programs for AIN457, Secukinumab (NCT05583604) | Novartis Pharmaceuticals | |
| Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC (NCT01947608) | Novartis Pharmaceuticals | |
| Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination (NCT01613053) | Novartis Pharmaceuticals | |
| Lamprene Multiple Patient Program (NCT04334070) | Novartis Pharmaceuticals | |